Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial

作者：Andrea Necchi, Mathieu Roumiguié, Ashish M. Kamat, Neal D. Shore, Joost L. Boormans, Adil Esen, Thierry Lebrét, Shuya Kandori, Dean F. Bajorin, Laurence Eliot Miles Krieger, Scot Anthony Niglio, Edward Uchio, Ho Kyung Seo, Ronald de Wit, Eric A. Singer, Petros D. Grivas, Hiroyuki Nishiyama, Haojie Li, Pranshu Baranwal, Margot Van den Sigtenhorst-Fijlstra, Ekta Kapadia, Girish S. Kulkarni · 发表于：The Lancet Oncology · 年份：2024 · DOI：10.1016/s1470-2045(24)00178-5 · 被引用次数：95 · 研究领域：Bladder and Urothelial Cancer Treatments、Immune responses and vaccinations、Cancer Immunotherapy and Biomarkers